Silo Pharma is a developmental stage biopharmaceutical company headquartered in New Jersey. At the helm is investor and CEO Eric Weisblum, who founded the company in 2010. Silo’s mission is to use and fund cutting-edge psychedelic research that transforms treatment paradigms in the medical and psychedelic therapy space. Its focus is on combining generic medications with substances like psilocybin, MDMA, and LSD in the treatment of under-addressed mental health and neurological conditions such as Parkinson’s, PTSD, and fibromyalgia. Silo is pursuing applications such as low-dose LSD and low-dose psilocybin to address cognitive, emotional dysfunction in Parkinson’s patients and psilocybin for cancer patients.
The company’s commercialization approach involves partnerships with leading medical universities and pharmaceutical companies, as well as securing Breakthrough Therapy, Orphan, and Fast Track FDA designations. As of winter 2021, Silo’s IP portfolio included provisional patent applications filed for central nervous system delivery methods of psilocybin, and psilocybin used in cancer treatment.